Suzhou Highfine Biotech Past Earnings Performance
Past criteria checks 5/6
Suzhou Highfine Biotech has been growing earnings at an average annual rate of 9.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.4% per year. Suzhou Highfine Biotech's return on equity is 5.2%, and it has net margins of 28.2%.
Key information
9.4%
Earnings growth rate
4.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 8.4% |
| Return on equity | 5.2% |
| Net Margin | 28.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Suzhou Highfine Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 413 | 116 | 42 | 35 |
| 30 Jun 24 | 404 | 106 | 45 | 34 |
| 31 Mar 24 | 355 | 93 | 37 | 34 |
| 31 Dec 23 | 389 | 99 | 36 | 28 |
| 30 Sep 23 | 390 | 105 | 33 | 26 |
| 30 Jun 23 | 387 | 114 | 26 | 21 |
| 31 Mar 23 | 437 | 128 | 26 | 21 |
| 01 Jan 23 | 447 | 129 | 25 | 22 |
| 30 Sep 22 | 465 | 134 | 26 | 21 |
| 30 Jun 22 | 480 | 136 | 29 | 21 |
| 31 Mar 22 | 425 | 124 | 27 | 18 |
| 31 Dec 21 | 369 | 111 | 26 | 15 |
| 31 Dec 20 | 282 | 40 | 50 | 22 |
| 31 Dec 19 | 191 | 58 | 17 | 8 |
| 31 Dec 18 | 142 | 40 | 13 | 7 |
| 30 Sep 18 | 132 | 38 | 11 | 8 |
| 30 Jun 18 | 122 | 31 | 17 | 1 |
| 31 Mar 18 | 108 | 27 | 17 | 0 |
| 31 Dec 17 | 94 | 23 | 9 | 7 |
| 30 Sep 17 | 93 | 22 | 10 | 5 |
| 30 Jun 17 | 93 | 22 | 11 | 3 |
| 31 Mar 17 | 90 | 20 | 13 | 2 |
| 31 Dec 16 | 88 | 19 | 14 | 0 |
| 30 Sep 16 | 82 | 16 | 13 | 0 |
| 30 Jun 16 | 77 | 14 | 13 | 0 |
| 31 Mar 16 | 71 | 12 | 12 | 0 |
| 31 Dec 15 | 66 | 9 | 12 | 0 |
| 31 Dec 14 | 50 | 3 | 9 | 0 |
| 31 Dec 13 | 34 | 2 | 8 | 0 |
Quality Earnings: 301393 has high quality earnings.
Growing Profit Margin: 301393's current net profit margins (28.2%) are higher than last year (26.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301393's earnings have grown by 9.4% per year over the past 5 years.
Accelerating Growth: 301393's earnings growth over the past year (10.7%) exceeds its 5-year average (9.4% per year).
Earnings vs Industry: 301393 earnings growth over the past year (10.7%) exceeded the Pharmaceuticals industry -1.2%.
Return on Equity
High ROE: 301393's Return on Equity (5.2%) is considered low.